Health and Me on MSN

Can A Rash Be A Sign Of COVID-19? Here’s Everything You Should Know

A growing number of people have reported developing unexpected skin rashes during or after a COVID-19 infection, leading ...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dos…

Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 ...

Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing ...

A case of membranoproliferative glomerulonephritis with immune depositions in the kidney was reported during clinical trials. Monitor serum creatinine and urinary protein-to-creatinine ratio. If ...

The Best Pet Insurance in Utah 2025

We examined costs and coverage in Utah to find the best options.
Le Lézard

Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio ...
Le Lézard

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter of 2025 and the completion of ESSENCE, its global, Phase ...